Clinical Significance of a Myeloperoxidase Gene Polymorphism and Inducible Nitric Oxide Synthase Expression in Cirrhotic Patients with Hepatopulmonary Syndrome
10.1007/s11596-010-0445-1
- Author:
WANG YANYING
1
;
WANG WENDUO
;
ZHANG YANXIA
;
ZHAO XIN
;
YANG DONGLIANG
Author Information
1. Department of Gastroenterology,Heilongjiang Provincial Hospital,Harbin 150036,China
- Keywords:
hepatopulmonary syndrome;
myeloperoxidase;
inducible nitric oxide synthase;
polymorphism
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2010;30(4):437-442
- CountryChina
- Language:Chinese
-
Abstract:
The clinical significance of a myetoperoxidase (MPO) gene polymorphism and inducible nitric oxide synthase (iNOS) expression in cirrhotic patients with hepatopulmonary syndrome (HPS) was explored. Enrolled subjects were divided into three groups according to their disease/health conditions: the HPS group (cirrhotic patients with HPS;n=63), the non-HPS group (cirrhotic patients without HPS;n=182), and the control group (healthy subjects without liver disease;n=35). The distribution of the MPO -463 G/A genotype and its relationship with iNOS expression in a typical cell block from as-citic fluid were detected by immunohistochemistry and polymerase chain reaction-restricted fragment length polymorphism analysis (PCR-RFLP). In the HPS group, the partial pressure of oxygen in blood and ascitic fluid was significantly decreased (8.95±1.58 kPa and 6.81±0.95 kPa, respectively;both P<0.01), while the partial pressure of carbon dioxide significantly increased (4.62±0.20 kPa and 5.92±0.45 kPa, respectively;P<0.01). MPO and iNOS levels were significantly increased in the HPS group as compared with the non-HPS group. These increases were even more remarkable in ascitic fluid (41.36±11.62 and 13.23±4.81 μg/L;10.27± 3.2 0 and 4.95±1.12 μg/L) than in blood (16.66±5.24 and 4.87±1.73 μg/L;5.79±2.31 and 2.35±0.84 μg/L). The distribution of the MPO genotypes GG, GA, and AA were 76.2%, 22.2% and 1.6% in the HPS group, and 57.7%, 37.9% and 4.4% in the non-HPS group (P<0.05). The expression of iNOS was significantly higher in patients with the G alleles (G/G and G/A) (61.54%, 48/78) than in patients with A alleles (G/A and A/A) (38.46%, 30/78) (P<0.01). It was suggested that the expression levels of iNOS and MPO were correlated with HPS-induced hypoxemia. The MPO-463 G/A mutation might be a protective factor that prevents the development of HPS. The MPO might be involved in the regulation of iNOS expression. In humans, MPO pathways, the iNOS/NO system, and their interaction might have an impact on the occurrence and development of HPS.
